Neogenix Oncology, Inc. announced that members of its scientific staff will present laboratory studies of NEO-201, a novel monoclonal antibody in development to diagnose and treat solid tumors of the gastrointestinal tract, lung and respiratory tract, breast, and ovarian cancers...
More...